Metabolomics in CKD patients: searching new biomarkers

• Grant number: 15/25329-0
• Support Opportunities: Scholarships abroad - Research
• Start date: August 15, 2016
• End date: August 14, 2017
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Silvia Maria de Oliveira Titan
• Grantee: Silvia Maria de Oliveira Titan
• Host Investigator: Ravi I. Thadhani
• Host Institution: Faculdade de Medicina (FM). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Institution abroad: Harvard University, Boston, United States

Abstract

CKD has become a major health problem worldwide. The morbidity and mortality related to CKD is very high, and the costs associated with this condition are increasing. Despite this reality, we have few biomarkers of this disease, resulting in limitations regarding our ability in diagnosis, prognosis and treatment of CKD. The search for new biomarkers of renal function and uremia is intense and actual. In this sense, metabolomics is a promissing technique, but research is still incipient in this field. The objective of our study is to explore potential biomarkers using metabolomics in urine and blood samples of 454 participants of the PROGREDIR Cohort. This is an ongoing CKD cohort, with an available biobank and ongoing prospective data collection. In the short run, using a cross-sectional approach with baseline data, we will evaluate the role of potential biomarkers regarding the degree of renal dysfunction, albuminuria, calcification, cardiac hypertrophy and other cardiovascular risk factors. In the long run, metabolomics data could be tested against clinical outcomes of the cohort, such as mortality, renal replacement therapy and cardiovascular events. (AU)